Free Trial
NASDAQ:EFTR

eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

eFFECTOR Therapeutics logo
$0.0002 0.00 (0.00%)
As of 04/24/2025 02:49 PM Eastern

About eFFECTOR Therapeutics Stock (NASDAQ:EFTR)

Key Stats

Today's Range
$0.0002
$0.0002
50-Day Range
N/A
52-Week Range
$0.00
$2.34
Volume
4,001 shs
Average Volume
2,354 shs
Market Capitalization
$940.80
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EFTR Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Elon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.
See More Headlines

EFTR Stock Analysis - Frequently Asked Questions

eFFECTOR Therapeutics' stock was trading at $0.0002 at the beginning of the year. Since then, EFTR stock has increased by 0.0% and is now trading at $0.0002.
View the best growth stocks for 2025 here
.

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) issued its quarterly earnings data on Monday, November, 8th. The company reported $10.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.50) by $17.00. The company had revenue of $0.43 million for the quarter.

Shares of eFFECTOR Therapeutics reverse split before market open on Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that eFFECTOR Therapeutics investors own include HubSpot (HUBS), Netflix (NFLX), Tesla (TSLA), Athenex (ATNX), ForgeRock (FORG) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/08/2021
Today
4/25/2025
Next Earnings (Estimated)
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EFTR
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.55 million
Price / Cash Flow
N/A
Book Value
($1.94) per share
Price / Book
0.00

Miscellaneous

Free Float
4,483,000
Market Cap
$940.80
Optionable
No Data
Beta
0.44
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:EFTR) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners